|Dr. Thomas J. Schuetz||Co-Founder, CEO & Director||4k||N/A||1961|
|Dr. Vered Bisker-Leib Ph.D., MBA||COO & Pres||520k||N/A||1971|
|Mr. Neil L. Lerner CPA||VP of Fin.||N/A||N/A||1968|
|Dr. Susan Kalled Ph.D.||Chief Scientific Officer||N/A||N/A||N/A|
Compass Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing antibody therapeutics for treating solid tumors and hematological malignancies. The company's lead product candidate is CTX-471, a monoclonal antibody agonist of CD137, a co-stimulatory receptor on immune cells that is in Phase 1b clinical trial. It also plans to initiate a second Phase 1 trial of CTX-471 in combination with trastuzumab for Her2 positive tumors, as well as with cetuximab in EGFR positive tumors. In addition, the company's product candidates include CTX-8371, a bispecific antibody that targets PD-1 and PD-L1. Further, it is developing a portfolio of bispecific and monoclonal antibody product candidates, which are in preclinical development. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Compass Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.